TBX1 and neoplasm: We show here that ProAgio enhances aPDL-1 treatment effectiveness in the following ways (Figure 5G): (1) the alteration of tumor immunity due to the depletion of CAFs and tumor angiogenesis, (2) the increase in tumor blood perfusion, and thus an increase in the infiltration of aPDL-1 due to the elimination of leaky and disorganized angiogenic tumor vessels, (3) the enhancement of anti-tumor immunity due to a decrease in tumor hypoxia, and (4) the removal of the molecular trap of aPDL-1 due to the depletion of activated CAFs.